Loading
A phase 1/2 trial of Nivolumab in ovarian cancer and non-small-cell lung cancer, run by BicycleTx Limited, active and no longer recruiting.
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression is a phase 1/2 interventional study registered as NCT04180371 by BicycleTx Limited, with 288 participants planned, started 2019-11-07 and due to reach its primary completion in 2026-07-31. Interventions recorded: BT5528, Nivolumab. Conditions listed: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bicycle Therapeutics, Nivolumab, Immune checkpoint inhibitors.
Shares Bicycle Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Bicycle Therapeutics, Ovarian cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/